Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

June 12, 2018 – Will accelerate discovery of next-generation immunodementia therapeutics that go beyond A-beta and tau by targeting immune mechanisms identified by human genetics – Represents significant 10-year investment by Eisai for drug discovery through novel integration of human

Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types

Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types

June 3, 2018 — First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the

Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)

Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)

May 30, 2018 – Designation underscores the need to expand potential treatment options to help certain young patients achieve goal of seizure freedom WOODCLIFF LAKE, N.J., May 30, 2018 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA)